HEMLIBRA contains the active substance Emicizumab. It is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors. Heamophilia A is a genetic bleeding condition caused by a lack of factor VIII, which is essential factor for blood clotting. This medicine helps the blood to clot normally. It belongs to a group of medicines called monoclonal antibodies. They are specialized proteins designed to recognize and attach to specific targets in the body. The medicine prevents bleeding or reduces bleeding episodes in people with this condition.

 Inform the doctor if you have any pre-existing or a history of liver/kidney disease, active infections, breathing problems, weak immune system, skin problems or any other disease.

Inform the doctor about all your medical conditions, prescription and non-prescription drugs, vitamin supplements, herbal medications, since HEMLIBRA can interact with them. HEMLIBRA can cause an allergic reaction in some patients therefore it is necessary to read the complete composition list and consult the doctor in case of any ingredient that induces allergies.

Consult the doctor if you are planning, on a pregnancy or breastfeeding.
It is advisable to avoid driving and operating heavy machinery during the course of HEMLIBRA.